A MULTI-CENTER, DOUBLE-DUMMY, DOUBLE-BLIND STUDY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) COMPARED WITH INTRAVENEOUS (IV) ABA IN JAPANESE RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE

被引：3
|
作者：
Matsubara, T. [1 ]
Inoue, H. [2 ]
Iwahashi, M. [3 ]
Yamazaki, A. [4 ]
Takeuchi, T. [5 ]
机构：
[1] Matsubara Mayflower Hosp, Dept Orthoped, Kato, Japan
[2] Inoue Hosp, Takasaki, Gunma, Japan
[3] Higashihiroshima Mem Hosp, Hiroshima, Japan
[4] Bristol Myers KK, Clin Strategy, Tokyo, Japan
[5] Keio Univ, Dept Rheumatol, Tokyo, Japan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
D O I：
10.1136/annrheumdis-2012-eular.2090
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：197 / 197
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study
    Yang, Yue
    Li, Jingyang
    Liu, Ju
    Liu, Lin
    Wang, Yongfu
    Hu, Jiankang
    Li, Zhijun
    Gu, Jieruo
    Zhang, Xiao
    Xiao, Zhengyu
    Zheng, Junjie
    Liu, Lin
    Li, Zhanguo
    Wei, James Cheng-Chung
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 42
  • [42] Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression
    Mitsukuni Murasaki
    Tsukasa Koyama
    Shigenobu Kanba
    Masahiro Takeuchi
    Yuriko Shimizu
    Eri Arita
    Kentaro Kuroishi
    Masahiro Takeuchi
    Shinya Kamei
    Psychopharmacology, 2018, 235 : 2859 - 2869
  • [43] Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression
    Murasaki, Mitsukuni
    Koyama, Tsukasa
    Kanba, Shigenobu
    Takeuchi, Masahiro
    Shimizu, Yuriko
    Arita, Eri
    Kuroishi, Kentaro
    Takeuchi, Masahiro
    Kamei, Shinya
    PSYCHOPHARMACOLOGY, 2018, 235 (10) : 2859 - 2869
  • [44] Two-Year Results of Envarsus (Once-Daily MeltDose Tacrolimus Tablets) vs Prograf (Twice-Daily Tacrolimus Capsules): A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study
    Rostaing, L.
    Ciechanowski, K.
    Bunnapradist, S.
    Silva, H., Jr.
    Grinyo, J.
    Budde, K.
    TRANSPLANTATION, 2014, 98 : 661 - 662
  • [45] ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study
    Genovese, Mark C.
    Weinblatt, Michael E.
    Aelion, Jacob A.
    Mansikka, Heikki T.
    Peloso, Paul M.
    Chen, Kun
    Li, Yihan
    Othman, Ahmed A.
    Khatri, Amit
    Khan, Nasser S.
    Padley, Robert J.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (11) : 1710 - 1720
  • [46] A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period (vol 28, pg 76, 2017)
    Ogata, Atsushi
    Tanaka, Yoshiya
    Ishii, Tomonori
    Kaneko, Motohide
    Miwa, Hiroko
    Ohsawa, Shino
    MODERN RHEUMATOLOGY, 2018, 28 (01) : V - V
  • [47] Two-Year Results of Envarsus (Once-Daily MeltDose Tacrolimus Tablets) vs Prograf (Twice-Daily Tacrolimus Capsules): A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study.
    Rostaing, L.
    Ciechanowski, K.
    Bunnapradist, S.
    Silva, H., Jr.
    Grinyo, J.
    Budde, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 661 - 662
  • [48] CLINICAL-EVALUATION OF LOBENZARIT (CCA), A NON-ANTIINFLAMMATORY IMMUNODULATIVE, IN RHEUMATOID-ARTHRITIS (RA) - A MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    SHIOKAWA, Y
    INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1982, 4 (04): : 318 - 318
  • [49] SUMMACTA: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY OF THE SAFETY AND EFFICACY OF TOCILIZUMAB SUBCUTANEOUS (SC) VERSUS TOCILIZUMAB INTRAVENOUS (IV), IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS (RA)
    Hall, S.
    Bird, P.
    Rischmueller, M.
    Rubbert-Roth, A.
    Cantagrel, A.
    Leszczynski, P.
    Feldman, D.
    Rangaraj, M.
    Roane, G.
    Ludivico, C.
    Mysler, E.
    Rowell, L.
    Douglass, W.
    Burmester, G.
    INTERNAL MEDICINE JOURNAL, 2013, 43 : 13 - 13
  • [50] Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate
    Weinblatt, Michael
    Genovese, Mark C.
    Ho, Meilien
    Hollis, Sally
    Rosiak-Jedrychowicz, Krystyna
    Kavanaugh, Arthur
    Millson, David
    Leon, Gustavo
    Wang, Millie
    van der Heijde, Desiree
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S763 - S764
12345